U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163325) titled 'EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors' on Aug. 05.
Brief Summary: This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies.
This study will inform on recommended doses for further studies, e.g. dose optimization studies and / or efficacy and safety studie...